Анализ взаимосвязи иммунологических факторов и воспалительных маркеров с течением хронической сердечной недостаточности на фоне ревматоидного артрита
https://doi.org/10.18087/cardio.2495
Аннотация
Список литературы
1. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007;93 (9):1137-46. DOI:10.1136/hrt. 2003.025270
2. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность ХСН в Европейской части Российской Федерации - данные ЭПОХА - ХСН (Часть II). Журнал Сердечная Недостаточность. 2006;7 (3):112-5.
3. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Журнал Сердечная Недостаточность. 2011;12 (2):63-8. DOI:10.18087/rhfj. 2011.2.1510
4. Фомин И. В. Хроническая СН в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7-13. DOI:10.15829/1560-4071-2016-8-7-13
5. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А., и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017;18 (1):3-40. DOI:10.18087/rhfj. 2017.1.2346
6. Ponikowski P., Voors AA, Anker SD, Bueno H., ClelandJGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: "Шє Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37 (27):2129-200. DOI:10.1093/eurheartj/ehw128
7. Dickson VV, Buck H, Riegel B. A Qualitative Meta-Analysis of Heart Failure Self-Care Practices Among Individuals With Multiple Co-morbid Conditions. Journal of Cardiac Failure. 2011,17 (5):413-9. DOI:10.1016/j. cardfail. 2010.11.011
8. Fortin M, Stewart M, Poitras M-E, Almirall J, Maddocks H. A Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. The Annals of Family Medicine. 2012,10 (2):142-51. DOI:10.1370/afm. 1337
9. Carmona M, Garcia-Olmos LM, Alberquilla A, Munoz A, Garcia-Sagredo P, Somolinos R et al. Heart failure in the family practice: a study of the prevalence and co-morbidity. Family Practice. 2011,28 (2): 128-33. DOI:10.1093/fampra/cmq084
10. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey: Co-morbidities in heart failure. EuropeanJournal of Heart Failure. 2014,16 (1):103-11. DOI:10.1002/ejhf. 30
11. Серов В. А., Шутов А. М., Мензоров М. В., Макеева Е. Р., Серова Д. В. Эпидемиология хронической болезни почек у больных ХСН. Нефрология. 2010,-14 ( 1 ):50-5. [Serov V. A., Shutov A. M., Menzorov M. V, Makeeva E. R., Serova D. V Epidemiology of chronic kidney disease patients with chronic heart failure. Nephrology (Saint-Petersburg). 2010,14 (1):50-55. https://doi.org/10.24884/1561-6274-2010-14-1-50-55]
12. Strongin L G, Pochinka I G, Konysheva M S, Morozova E P. Glycemic control on development of chronic heart failure in patients with type 2 diabetes mellitus. Diabetes mellitus. 2012,15 (2):17. DOI:10.14341 / 2072-0351-5513
13. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM et al. OARSI guidelines for the non-surgical management ofknee osteoarthritis. Osteoarthritis and Cartilage. 2014,22 (3):363-88. DOI:10.1016/j. joca. 2014.01.003
14. Lindman BR. The Diabetic Heart Failure With Preserved Ejection Fraction Phenotype: Is it Real and Is It Worth Targeting Therapeutically? Circulation. 2017,135 (8):736-40. DOI:10.1161/CIRCULA-TIONAHA. 116.025957
15. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Failure Reviews. 2014,19 (5):681-94. DOI:10.1007/s10741-013-9405-8
16. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K et al. Pentraxin 3 Is a New Inflammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection Fraction. Journal of the American College of Cardiology. 2011,57 (7):861-9. DOI:10.1016/j. jacc. 2010.10.018
17. Balling L, Gustafsson F. Copeptin as a biomarker in heart failure. Biomarkers in Medicine. 2014,8 (6):841-54. DOI:10.2217/bmm. 14.50
18. Van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MPV Bronzwaer JGF et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012,126 (7):830-9. DOI: 10.1161/CIRCULATIONAHA. 111.076075
19. van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006,48 (6):1217-24. DOI:10.1016 /j. jacc. 2006.03.061
20. Lok DJA, Van Der Meer P, de la Porte PWB-A, Lipsic E, Van Wijngaarden J, Hillege HL et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010,99 (5):323-8. DOI:10.1007/s00392-010-0125-y
21. Xie Q, Ni M, Wang S-C. Galectin-3, A Potential Therapeutic Target For Rheumatoid Arthritis? Scandinavian Journal of Immunology. 2018,87 (2):108-108. DOI:10.1111/sji. 12631
22. Issa SF, Christensen AF, Lindegaard HM, Hetland ML, Horslev-Petersen K, Stengaard-Pedersen K et al. Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (^A) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity. Scandinavian Journal of Immunology. 2017,86 (6):471-8. DOI:10.1111/ sji. 12619
23. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. American Heart Journal. 2008,155 (1):75-81. DOI:10.1016/j. ahj. 2007.08.013
24. Huang X, Zhang L, Duan Y, Wang Y, Wang J. Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis. Archives of Medical Research. 2016,47 (3):223-31. DOI:10.1016/j. arcmed. 2016.05.006
25. Kopytsya M, Vyshnevska I, Protsenko O, Barahmeh H. Growth differentiation factor 15 as a prognostic marker ofchronic heart failure progression in long-term follow-up after acute coronary syndrome. Georgian Med News. 2017, (271):61-6. PMID:29099703
26. Zhu ZD, Sun T. Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients. Genetics and Molecular Research. 2015,14 (1):2225-33. DOI:10.4238/2015. March. 27.8
27. Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, Kusaka H et al. Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology. 2014,30 (3):338-44. DOI:10.1016/j. cjca. 2013.12.010
28. Arlestig L, Rantapaa-Dahlqvist S. Polymorphisms of the Genes Encoding CD40 and Growth Differentiation Factor 15 and in the 9p21.3 Region in Patients with Rheumatoid Arthritis and Cardiovascular Disease. The Journal of Rheumatology. 2012,39 (5):939-45. DOI:10.3899/jrheum. 111336
29. Amaya-Amaya J, Rojas-Villarraga A, Molano-Gonzalez N, Montoya-Sanchez L, Nath SK, Anaya J-M. GDF15 (MIC1) H6D Polymorphism Does Not Influence Cardiovascular Disease in a Latin American Population with Rheumatoid Arthritis. Journal of Immunology Research. 2015,2015:1-9. DOI:10.1155/2015/270763
30. Luukkonen J, Pascual LM, Patlaka C, Lang P, Turunen S, Halleen J et al. Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritis synovia is associated to decreased tartrate-resistant acid phosphatase 5B / 5A ratio. Ria F, editor. PLOS ONE. 2017,12 (8):e0182904. DOI:10.1371/journal. pone. 0182904
31. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology. 2005,44 (5):677-80. DOI:10.1093/rheumatology/keh610
32. Filhol E, Gaujoux-Viala C, Combe B, Morel J, Hua C, Nutz A et al. OP0146 Decrease in cardiovascular event excess risk in rheumatoid arthritis since 2000»: a meta- analysis ofcontrolled studies. Oral Presentations [Internet]. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017Jun [cited 2018]. p. 113.1-113.
Рецензия
Для цитирования:
Анкудинов А.С., Калягин А.Н. Анализ взаимосвязи иммунологических факторов и воспалительных маркеров с течением хронической сердечной недостаточности на фоне ревматоидного артрита. Кардиология. 2018;58(10S):4-8. https://doi.org/10.18087/cardio.2495
For citation:
Ankudinov A.S., Kalyagin A.N. Analysis of the interrelation between immune factors and inflammatory markers, and the course of chronic heart failiure in patients with rheumathoid arthritis. Kardiologiia. 2018;58(10S):4-8. (In Russ.) https://doi.org/10.18087/cardio.2495